No Data
No Data
Buy Rating Affirmed for Armata Pharmaceuticals Amid Progress in Bacteriophage Therapy Development
Armata Pharmaceuticals Inc (ARMP) Earnings: Navigates Through R&D to Narrow Losses
Armata Pharmaceuticals Under Pressure: Navigating the Risks as Cost-Cutting Measures Threaten Revenue
Armata Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Armata Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Armata Pharmaceuticals, Maintains $7 Price Target
HC Wainwright & Co. analyst Joseph Pantginis maintains Armata Pharmaceuticals (AMEX:ARMP) with a Buy and maintains $7 price target.
Armata Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/22/2024 101.15% HC Wainwright & Co. $7 → $7 Maintains Buy 08/14/2023 101.15% HC Wainwright & Co. $7 → $
No Data